FDA: Drug shows some sarcoma survival gains
The drug Votrient extended the lives of a significant number of patients suffering from an aggressive form of cancer without the disease getting worse, but the drug did not improve overall survival rates, health regulators said. Food and Drug Administration staff said in a review the drug, known generically as pazopanib, has a safety profile for patients with soft-tissue sarcoma that is similar to indications for renal cell carcinoma.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063